KCL-286 is an orally active and brain-penetrant retinoic acid receptor (RAR) β2 agonist. It targets RARβ2 with selectivity over RAR α and RAR γ, activating RARβ2 in injured neurons. This compound induces axonal regeneration of both spinal and sensory nerves through the inhibitory environment of the CNS, modulates neuroinflammation, and extracellular matrix molecules.
- Orally active and brain-penetrant RAR β2 agonist
- Selectivity for RARβ2 over RAR α and RAR γ
- Activates RARβ2 in injured neurons
- Induces axonal regeneration of spinal and sensory nerves
- Modulates neuroinflammation and extracellular matrix molecules
- Can modulate CSPG expression by neuronal secretion of decorin to promote myelination and axonal growth
- Potential for research in spinal cord injury and traumatic nerve injury